Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer

Reuters

09/29

Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer

Veracyte Inc. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2571824837"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571824837\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571824837?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 04:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571824837","market":"nz","top_or_hot":-1,"title":"Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VCYT\">Veracyte Inc</a>. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-29 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VCYT\">Veracyte Inc</a>. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250928:nNDL6gfl3Y:1","article_id":"2571824837","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571824837","pubTimestamp":1759089621,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer. Veracyte Inc. has announced new data from the prospective, randomized BALANCE trial , indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology  in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligenc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VCYT":"Veracyte Inc"},"translate_title":"Veracyte公布里程碑式临床试验结果：PAM50生物标志物预测复发性前列腺癌的激素治疗获益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":0.9},"content_text":"Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n    \n\nVeracyte Inc. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}